| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/KI.2013.291 |
| P698 | PubMed publication ID | 23945498 |
| P50 | author | Takayuki Yamamoto | Q55294070 |
| P2093 | author name string | Takaaki Kobayashi | |
| Satoshi Ashimine | |||
| Koji Nanmoku | |||
| Makoto Tsujita | |||
| Norihiko Goto | |||
| Takahisa Hiramitsu | |||
| Yoshihiko Watarai | |||
| Kazuharu Uchida | |||
| Asami Takeda | |||
| Akio Katayama | |||
| P2860 | cites work | Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression | Q83748536 |
| De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy | Q84464302 | ||
| A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up | Q84749610 | ||
| Rituximab in renal transplantation | Q27026434 | ||
| Non-infectious pulmonary toxicity of rituximab: a systematic review | Q34096300 | ||
| Effect of antibodies on endothelium | Q35547335 | ||
| Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin | Q35664634 | ||
| Antibody-mediated rejection in kidney transplantation: a review | Q35915453 | ||
| Antibody mediated rejection: update 2006. | Q36910384 | ||
| Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes | Q37300446 | ||
| Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. | Q37572815 | ||
| Solid phase assays for HLA antibody detection in clinical transplantation | Q37600156 | ||
| Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature | Q37786488 | ||
| B-cell immunotherapeutics: emerging roles in solid organ transplantation | Q37888431 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| Prevention of antibody-mediated kidney transplant rejection | Q38010231 | ||
| Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy | Q38062943 | ||
| Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study | Q39883589 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation | Q44722151 | ||
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts | Q45287212 | ||
| A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. | Q45304143 | ||
| Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy | Q45356997 | ||
| Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens | Q46135152 | ||
| ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment | Q46702772 | ||
| HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway | Q46907583 | ||
| Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules | Q47272995 | ||
| Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation | Q47722275 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. | Q50765005 | ||
| Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. | Q54345873 | ||
| The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. | Q54410910 | ||
| Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. | Q54481297 | ||
| Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction: implication of accommodation. | Q54538215 | ||
| Pharmacodynamics of Rituximab in Kidney Allotransplantation | Q62588643 | ||
| Analysis of HLA class I specific antibodies in patients with failed allografts | Q79552590 | ||
| Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation | Q82046014 | ||
| Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant | Q82343270 | ||
| Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period | Q82350692 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| Humoral antibodies in organ transplantation: angels or demons? | Q82732544 | ||
| Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients | Q83186380 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| rituximab | Q412323 | ||
| P304 | page(s) | 425-430 | |
| P577 | publication date | 2013-08-14 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation | |
| P478 | volume | 85 |
| Q92352863 | A Case of Small Intestinal Ileus Due to Wandering Spleen with a Large Cyst |
| Q40879749 | ABO desensitization affects cellular immunity and infection control after renal transplantation |
| Q28236829 | ABO incompatible renal transplants: Good or bad? |
| Q90252745 | ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis |
| Q40915460 | ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management |
| Q38267202 | An update on ABO-incompatible kidney transplantation |
| Q64969788 | Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? |
| Q90047669 | Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis |
| Q36171175 | Current progress in ABO-incompatible kidney transplantation |
| Q64098171 | Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience |
| Q41310084 | Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation |
| Q40100407 | Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment. |
| Q35097898 | HLA sensitisation: can it be prevented? |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q90112402 | Latest insights on ABO-incompatible living-donor renal transplantation |
| Q53610974 | Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. |
| Q35565364 | One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts |
| Q46610169 | Risk factors for the development of donor-specific antibodies after pediatric heart transplantation. |
| Q85930744 | Splenectomy attenuates the course of kidney ischemia-reperfusion injury in rats |
| Q38577657 | Strategies to overcome the ABO barrier in kidney transplantation |
| Q26774993 | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients |
| Q46667967 | Transplantation: rituximab induction only for sensitized kidney recipients? |
Search more.